Nebula Research & Development LLC Makes New $231,000 Investment in AnaptysBio, Inc. (NASDAQ:ANAB)

Nebula Research & Development LLC purchased a new position in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 17,422 shares of the biotechnology company's stock, valued at approximately $231,000. Nebula Research & Development LLC owned about 0.06% of AnaptysBio as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Vanguard Group Inc. increased its stake in shares of AnaptysBio by 8.4% in the fourth quarter. Vanguard Group Inc. now owns 1,843,740 shares of the biotechnology company's stock worth $24,411,000 after purchasing an additional 143,584 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in AnaptysBio by 41.0% in the 4th quarter. Victory Capital Management Inc. now owns 334,450 shares of the biotechnology company's stock worth $4,428,000 after buying an additional 97,200 shares during the period. JPMorgan Chase & Co. grew its stake in AnaptysBio by 240.6% in the 4th quarter. JPMorgan Chase & Co. now owns 114,939 shares of the biotechnology company's stock valued at $1,522,000 after buying an additional 81,195 shares in the last quarter. Barclays PLC raised its holdings in AnaptysBio by 88.6% during the 4th quarter. Barclays PLC now owns 83,567 shares of the biotechnology company's stock valued at $1,107,000 after acquiring an additional 39,267 shares during the period. Finally, Y Intercept Hong Kong Ltd bought a new stake in AnaptysBio during the 4th quarter valued at $311,000.

AnaptysBio Trading Down 1.8 %

Shares of NASDAQ ANAB traded down $0.36 during midday trading on Wednesday, hitting $19.76. 72,236 shares of the company's stock were exchanged, compared to its average volume of 591,269. The business's fifty day moving average price is $18.39 and its two-hundred day moving average price is $18.92. The company has a market cap of $584.38 million, a price-to-earnings ratio of -3.26 and a beta of -0.20. AnaptysBio, Inc. has a 12-month low of $12.21 and a 12-month high of $41.31.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The biotechnology company reported ($1.28) EPS for the quarter, topping analysts' consensus estimates of ($1.30) by $0.02. The firm had revenue of $27.77 million for the quarter, compared to analyst estimates of $15.27 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. Equities analysts expect that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

AnaptysBio announced that its board has authorized a share buyback plan on Monday, March 24th that permits the company to buyback $75.00 million in outstanding shares. This buyback authorization permits the biotechnology company to reacquire up to 13.1% of its stock through open market purchases. Stock buyback plans are typically a sign that the company's leadership believes its stock is undervalued.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. HC Wainwright reiterated a "neutral" rating and issued a $22.00 price target on shares of AnaptysBio in a research report on Tuesday, March 4th. Wells Fargo & Company lifted their target price on AnaptysBio from $40.00 to $51.00 and gave the company an "overweight" rating in a report on Thursday, February 13th. JPMorgan Chase & Co. upped their price target on AnaptysBio from $36.00 to $42.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Wolfe Research started coverage on shares of AnaptysBio in a research report on Tuesday, February 4th. They issued an "outperform" rating and a $25.00 price objective for the company. Finally, Wedbush reaffirmed an "outperform" rating and set a $40.00 price objective on shares of AnaptysBio in a research note on Thursday, May 1st. Four investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $35.88.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.